NASDAQ:REPH - Recro Pharma Stock Price, News, Headlines & Rumors

Sign in or create an account to add this stock to your watchlist.
$6.12 +0.30 (+5.15 %)
(As of 08/17/2018 04:00 PM ET)
Previous Close$5.82
Today's Range$5.77 - $6.15
52-Week Range$4.78 - $13.05
Volume74,500 shs
Average Volume270,187 shs
Market Capitalization$122.03 million
P/E Ratio-3.08
Dividend YieldN/A
Recro Pharma logoRecro Pharma, Inc., a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. The company's lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain. It also develops Dex-IN, an intranasal formulation of dexmedetomidine for treating post-operative pain and peri-procedural pain; two novel neuromuscular blocking agents and a related proprietary chemical reversal agent; and Fadolmidine for use in as human therapeutic. The company also provides contract development and manufacturing services. Recro Pharma, Inc. has a license agreement with Orion Corporation for the development and commercialization of Dexmedetomidine. It focuses on offering its products for hospitals and related markets. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was founded in 2007 and is based in Malvern, Pennsylvania.

Receive REPH News and Ratings via Email

Sign-up to receive the latest news and ratings for REPH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations


Debt-to-Equity Ratio2.22
Current Ratio1.59
Quick Ratio1.42


Trailing P/E Ratio-3.08
Forward P/E Ratio-2.43
P/E GrowthN/A

Sales & Book Value

Annual Sales$71.83 million
Price / Sales1.77
Cash FlowN/A
Price / CashN/A
Book Value$1.51 per share
Price / Book4.05


EPS (Most Recent Fiscal Year)($1.99)
Net Income$-50,080,000.00
Net Margins-75.19%
Return on Equity-144.84%
Return on Assets-25.87%


Outstanding Shares20,720,000
Market Cap$122.03 million

Recro Pharma (NASDAQ:REPH) Frequently Asked Questions

What is Recro Pharma's stock symbol?

Recro Pharma trades on the NASDAQ under the ticker symbol "REPH."

How were Recro Pharma's earnings last quarter?

Recro Pharma Inc (NASDAQ:REPH) posted its quarterly earnings data on Tuesday, August, 7th. The specialty pharmaceutical company reported ($0.62) EPS for the quarter, topping the Zacks' consensus estimate of ($1.34) by $0.72. The specialty pharmaceutical company earned $21.74 million during the quarter, compared to the consensus estimate of $16.81 million. Recro Pharma had a negative net margin of 75.19% and a negative return on equity of 144.84%. View Recro Pharma's Earnings History.

When is Recro Pharma's next earnings date?

Recro Pharma is scheduled to release their next quarterly earnings announcement on Thursday, November, 8th 2018. View Earnings Estimates for Recro Pharma.

What price target have analysts set for REPH?

7 Wall Street analysts have issued 12-month target prices for Recro Pharma's stock. Their forecasts range from $9.00 to $19.00. On average, they expect Recro Pharma's stock price to reach $13.20 in the next year. This suggests a possible upside of 115.7% from the stock's current price. View Analyst Price Targets for Recro Pharma.

What is the consensus analysts' recommendation for Recro Pharma?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Recro Pharma in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Recro Pharma.

Who are some of Recro Pharma's key competitors?

Who are Recro Pharma's key executives?

Recro Pharma's management team includes the folowing people:
  • Dr. Geraldine A. Henwood, CEO, Pres & Director (Age 66)
  • Mr. Michael Celano, COO & Corp. Sec. (Age 59)
  • Dr. Stewart McCallum, Chief Medical Officer (Age 52)
  • Mr. Ryan D. Lake, Chief Financial Officer (Age 41)
  • Mr. Randall J. Mack, Sr. VP of Devel. and Corp. Sec. (Age 53)

Has Recro Pharma been receiving favorable news coverage?

News articles about REPH stock have trended somewhat positive on Friday, Accern Sentiment Analysis reports. The research firm scores the sentiment of media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Recro Pharma earned a media and rumor sentiment score of 0.03 on Accern's scale. They also assigned media coverage about the specialty pharmaceutical company an impact score of 45.47 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future. View Recent Headlines for Recro Pharma.

Who are Recro Pharma's major shareholders?

Recro Pharma's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BROADFIN CAPITAL, LLC (9.99%), BlackRock Inc. (5.58%), Newtyn Management LLC (4.28%), Engine Capital Management LP (1.89%), Renaissance Technologies LLC (1.84%) and Sanders Morris Harris LLC (1.35%). Company insiders that own Recro Pharma stock include Alfred Altomari, Healthcare Master Fun Broadfin, James E Flynn, Karen Flynn, Scp Vitalife Partners (Israel), Scp Vitalife Partners Ii Lp and Stonepine Capital Management,. View Institutional Ownership Trends for Recro Pharma.

Which institutional investors are selling Recro Pharma stock?

REPH stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC and Schwab Charles Investment Management Inc.. Company insiders that have sold Recro Pharma company stock in the last year include Healthcare Master Fun Broadfin, Scp Vitalife Partners (Israel) and Scp Vitalife Partners Ii Lp. View Insider Buying and Selling for Recro Pharma.

Which institutional investors are buying Recro Pharma stock?

REPH stock was bought by a variety of institutional investors in the last quarter, including Newtyn Management LLC, Engine Capital Management LP, Sanders Morris Harris LLC, BlackRock Inc., Acadian Asset Management LLC, Spark Investment Management LLC, Los Angeles Capital Management & Equity Research Inc. and Orbimed Advisors LLC. Company insiders that have bought Recro Pharma stock in the last two years include Alfred Altomari, Healthcare Master Fun Broadfin and Karen Flynn. View Insider Buying and Selling for Recro Pharma.

How do I buy shares of Recro Pharma?

Shares of REPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Recro Pharma's stock price today?

One share of REPH stock can currently be purchased for approximately $6.12.

How big of a company is Recro Pharma?

Recro Pharma has a market capitalization of $122.03 million and generates $71.83 million in revenue each year. The specialty pharmaceutical company earns $-50,080,000.00 in net income (profit) each year or ($1.99) on an earnings per share basis. Recro Pharma employs 256 workers across the globe.

How can I contact Recro Pharma?

Recro Pharma's mailing address is 490 LAPP ROAD, MALVERN PA, 19355. The specialty pharmaceutical company can be reached via phone at 484-395-2470 or via email at [email protected]

MarketBeat Community Rating for Recro Pharma (NASDAQ REPH)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  209 (Vote Outperform)
Underperform Votes:  170 (Vote Underperform)
Total Votes:  379
MarketBeat's community ratings are surveys of what our community members think about Recro Pharma and other stocks. Vote "Outperform" if you believe REPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe REPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/17/2018 by Staff

Featured Article: Fundamental Analysis

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.